Newsletter January 2010
January 15 2010
Since BioPorto announced in 2009 that very positive results had been obtained in the development of the Company's new homogeneous NGAL test for acute kidney injury, inquirers have shown a great interest in the various formats in which a diagnostic test can be developed and whether the different test formats can be offered to the market at the same time. Download the present commentary from the right hand menu to get a more detailed account og the various formats in which the NGAL test can be supplied.
